88058-88-2
88058-88-2
Chemical Structure
Naxagolide
Synonym(s): (+)-PHNO; Dopazinol
- CAS No.: 88058-88-2
- Formula:C15H21NO2
- Molecular Weight:247.33
IUPAC Name: (4aR,10bR)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol
InChIKey: JCSREICEMHWFAY-HUUCEWRRSA-N
SMILES: OC1=CC2=C(C=C1)CC[C@]3([H])[C@]2([H])OCCN3CCC
Biological Activity: Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Naxagolide | 99.81% | Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naxagolide (Standard) | ≥98% | Naxagolide (Standard) is the analytical standard of Naxagolide. This product is intended for research and analytical applications. Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.98
HY-108236Naxagolide hydrochloride -
Similarity Score 0.98
HY-115192ent-Naxagolide hydrochloride -
Similarity Score 0.74
HY-100539PD 128907 -
Similarity Score 0.73
HY-100539APD 128907 hydrochloride -
Similarity Score 0.73
HY-110000(+)-PD 128907 hydrochloride -
Similarity Score 0.64
HY-108056PF 219061 -
Similarity Score 0.62
HY-1011027-Hydroxy-DPAT hydrobromide -
Similarity Score 0.62
HY-1340157-Hydroxy-DPAT -
Similarity Score 0.61
HY-1298907-Hydroxy-PIPAT -
Explore the MedChemAI to find more analogs
References
- [1]. G E Martin, et al. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO]. J Pharmacol Exp Ther. 1984 Sep;230(3):569-76. [Content Brief]
- [2]. E F Domino, et al. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther. 1993 Jun;265(3):1387-91. [Content Brief]
